Portola, BMS and Pfizer to collaborate on Eliquis and PRT4445
Portola, BMS and Pfizer aim to find out whether PRT4445 is a safe and effective antidote to Eliquis and other Factor Xa inhibitors.
Portola Pharmaceuticals, Bristol-Myers Squibb (BMS) and Pfizer have announced a new clinical collaboration agreement to conduct a proof-of-concept study using Portola's universal Factor Xa inhibitor antidote PRT4445 and the investigational oral Factor Xa inhibitor Eliquis (apixaban).
Eliquis has been developed for its anticoagulant properties, but as with other anticoagulants there is a risk of serious bleeding, for which an effective antidote is required.
The newly announced collaboration aims to determine whether PRT4445 has the potential to become the first approved agent to reverse the activity of Factor Xa inhibitors such as Eliquis.
It is anticipated that the clinical proof-of-concept study will commence before the end of the year, hopefully demonstrating the safety and effectiveness of PRT4445.
Upon initiation of the study, Portola will receive an undisclosed cash payment from BMS and Pfizer. The company will retain global development and commercialisation rights for its compound.
"This clinical collaboration brings together world-class expertise in the field of thrombosis from Bristol-Myers Squibb, Pfizer and Portola with the goal of accelerating the development of PRT4445 as an antidote to Eliquis, while allowing Portola to retain all rights to develop and commercialise the compound in the future," said William Lis, chief executive officer of Portola.
Brian Daniels, senior vice-president of global development and medical affairs at BMS, added that the company looks forward to working with its partner Pfizer and Portola to advance the understanding of the role of PRT4445 as a potential antidote.
Related News
-
News CPHI Podcast Series: the power of digital marketing in pharma
Digital marketing is a valuable tool for many industries, and the pharmaceutical and healthcare industry is no exception. The CPHI Podcast Series covers how marketing can be used by companies to increase their engagement and overcome challenges.&n... -
News Novel approach to creating sustainable packaging from rice husks
Researchers have created a new approach to the designing of eco-friendly nanofibres extracted from rice husks, addressing the critical need for sustainable packaging materials in food and biopharmaceutical products. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance